Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study
Young Lyu,Hongyup Ahn,Sangmo Hong,Cheol-Young Park
DOI: https://doi.org/10.2147/dddt.s492913
IF: 4.3188
2024-11-27
Drug Design Development and Therapy
Abstract:Young Sang Lyu, 1 Hongyup Ahn, 2 Sangmo Hong, 3 Cheol-Young Park 4 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea; 2 Department of Statistics, Dongguk University, Seoul, Republic of Korea; 3 Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea; 4 Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Correspondence: Cheol-Young Park, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro,Jongno-gu, Seoul, 03181, Republic of Korea, Email Purpose: To investigate the safety and effectiveness of naltrexone-bupropion in Korean adults with obesity. Patients and methods: This was a prospective, observational multicenter study from April 29, 2016, to April 28, 2022. Individuals with obesity with a body mass index of ≥ 30 kg/m 2 or ≥ 27 kg/m 2 who had obesity-related comorbidities were included. The naltrexone-bupropion dose was gradually titrated weekly from 8/90 to 32/360 mg and maintained at the maximum tolerated dose. In total, 612 and 300 individuals were evaluated for safety and effectiveness, respectively. Results: In total, 41.34% individuals reported drug-related adverse reactions, such as nausea (19.12%), headache (7.68%), and dizziness (5.23%). Older age and comorbidities were significantly associated with adverse events. At 12 weeks after reaching the maintenance dose, naltrexone-bupropion 32/360 mg resulted in the greatest weight reduction (− 7.21%) compared with other doses, which persisted at week 24 (− 7.69%). The naltrexone-bupropion 16/180 mg resulted in significant weight reduction, achieving − 5.99% and − 9.18% reductions at weeks 12 and 24, similar to that with naltrexone-bupropion 32/360 mg. Young age and no comorbidities were significantly associated > 5% weight reduction. Conclusion: Naltrexone-bupropion demonstrated marked stability and weight loss effectiveness, particularly in young individuals with obesity without comorbidities. Therefore, individualized treatment is necessary when prescribing naltrexone-bupropion. Keywords: naltrexone-bupropion, obesity management, post-marketing survey, weight loss efficacy, adverse events Obesity is a global health epidemic and its prevalence steadily increased over the past few decades. 1 The prevalence of obesity in Korea has also shown a continuous increase, rising from 30.2% in 2012 to 38.4% in 2021. 2 It is closely associated with various metabolic disorders, including hypertension, type 2 diabetes mellitus, and dyslipidemia, which exacerbate the disease burden and eventually lead to mortality. 3,4 Lifestyle modifications, such as diet and exercise, remain the cornerstone of obesity management; 5 however, these interventions alone may not provide sufficient and sustained weight loss for many individuals. 6 Pharmacotherapy has emerged as an adjunct treatment option for individuals struggling with obesity. Long-term treatment with anti-obesity medications is essential for effective obesity management, necessitating the establishment of drug safety and efficacy over extended periods. 7 Although many drugs have been developed for obesity, only a few have proven long-term safety, one of which is naltrexone-bupropion. 8,9 Naltrexone-bupropion was approved by the FDA (Food and Drug Administration) for long-term weight management in patients with obesity in 2014. Naltrexone, an opioid receptor antagonist, and bupropion, a dopamine and norepinephrine reuptake inhibitor, act synergistically to modulate appetite and energy balance. 10 This combination therapy has demonstrated efficacy in promoting weight loss by reducing food intake, enhancing energy expenditure, and improving metabolic parameters in clinical trials. 11–13 Despite the promising outcomes observed in randomized controlled trials (RCTs) and meta-analysis, 9,11–14 post-marketing surveillance is imperative for assessing the real-world effectiveness and safety profile of naltrexone-bupropion therapy. According to a study conducted in the United Kingdom, real-world evidence suggests that patients with type 2 diabetes using GLP-1 (Glucagon-Like Peptide-1) receptor agonists experience lower weight loss effects than those reported in clinical trials, with only a small proportion of patients achieving clinically significant weight reduction. 15 RCTs of anti-obesity medicat -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal